Finoriq research workspace

Allogene Therapeutics, Inc. (ALLO) Historical Metrics

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes. Review ALLO valuation ratios, fundamentals, and filing metrics on Finoriq.

Company Snapshot

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Company

Allogene Therapeutics, Inc. (ALLO)

Ticker

ALLO

Market Cap

$614.4M

Latest Price

$1.78

Industry

Biotech & Pharma

Open insider transactions

Allogene Therapeutics, Inc. (ALLO) Current Valuation Metrics

Static valuation preview for Allogene Therapeutics, Inc. (ALLO). Market data retrieved 2026-07-09. Filing currency USD.

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.